Skip to content

IMPEDE and IMPEDE-FX Embolization Plug Registry

Post Market Registry of the IMPEDE and IMPEDE-FX Embolization Plugs

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04044443
Acronym
EMBO-PMS
Enrollment
108
Registered
2019-08-05
Start date
2019-07-09
Completion date
2026-09-30
Last updated
2025-12-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Vascular Embolization

Brief summary

EMBO-PMS is a prospective, multicentre, registry study of the IMPEDE and IMPEDE-FX Embolization Plug Systems

Interventions

DEVICEIMPEDE, IMPEDE-FX or IMPEDE-FX RapidFill

Peripheral vascular embolization

Sponsors

Shape Memory Medical, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Study participant is ≥18 years of age * Study participant is considered a candidate for arterial or venous embolization of the peripheral vasculature

Exclusion criteria

* Study participant has an inability to provide written informed consent * Study participant/treatment outside of the approved study device labeling, instructions for use (IFU) * Study participant is a prisoner or member of other vulnerable population

Design outcomes

Primary

MeasureTime frameDescription
Safety - Rate of freedom from serious adverse events30 daysRate of freedom from serious adverse events related to the study devices and/or procedure, per review and adjudication by medical monitor
Efficacy - Rate of technical success (embolization of target vessel)Immediately after the interventionTechnical success, defined as embolization of the target area after deployment of the study device

Secondary

MeasureTime frameDescription
Efficacy - Rate of recurrence of clinical symptoms, based on original complaint90 daysNumber of participants free of recurrent clinical symptoms, based on clinical symptoms of original complaint
Efficacy - Rate of treated vessel occlusion90 daysTreated vessel occlusion, measured per study site standard of care for the original condition treated
Safety - Rate of freedom from serious adverse events90 daysRate of freedom from serious adverse events related to the study devices and/or procedure, per review and adjudication by medical monitor

Countries

Germany, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026